Kazia Therapeutics Ltd
NV9
Company Profile
Business description
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
Contact
300 Barangaroo Avenue
Level 24
Three International Towers
SydneyNSW2000
AUST: +61 294724101
E: investment.consultant@novogen.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,622.50 | 9.00 | -0.10% |
| CAC 40 | 7,826.79 | 1.34 | -0.02% |
| DAX 40 | 24,226.49 | 198.84 | 0.83% |
| Dow JONES (US) | 42,343.65 | 740.58 | 1.78% |
| FTSE 100 | 8,778.05 | 60.08 | 0.69% |
| HKSE | 23,254.45 | 127.54 | -0.55% |
| NASDAQ | 19,199.16 | 461.96 | 2.47% |
| Nikkei 225 | 37,805.71 | 81.60 | 0.22% |
| NZX 50 Index | 12,381.10 | 201.23 | -1.60% |
| S&P 500 | 5,921.54 | 118.72 | 2.05% |
| S&P/ASX 200 | 8,393.70 | 13.90 | -0.17% |
| SSE Composite Index | 3,342.93 | 2.24 | 0.07% |